Bicara Therapeutics Inc. Common Stock - Asset Resilience Ratio

Latest as of September 2025: 27.90%

Bicara Therapeutics Inc. Common Stock (BCAX) has an Asset Resilience Ratio of 27.90% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bicara Therapeutics Inc. Common Stock (BCAX) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

$118.49 Million

Cash + Short-term Investments

Total Assets

$424.69 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Bicara Therapeutics Inc. Common Stock's Asset Resilience Ratio has changed over time. See BCAX book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Bicara Therapeutics Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BCAX company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$118.49 Million	27.9%
Total Liquid Assets	$118.49 Million	27.90%

Asset Resilience Insights

Very High Liquidity: Bicara Therapeutics Inc. Common Stock maintains exceptional liquid asset reserves at 27.90% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Bicara Therapeutics Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare Bicara Therapeutics Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Bicara Therapeutics Inc. Common Stock (None–None)

The table below shows the annual Asset Resilience Ratio data for Bicara Therapeutics Inc. Common Stock.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX USA Biotechnology

Market Cap

$1.40 Billion

Market Cap Rank

#8052 Global

#2236 in USA

Share Price

$21.67

Change (1 day)

+0.42%

52-Week Range

$8.71 - $24.01

All Time High

$27.07